BWA vs DDS

BorgWarner Inc. (BWA) exhibits weak fundamental health with a Piotroski F-Score of 4/9, indicating marginal stability, and lacks an Altman Z-Score, raising concerns about financial distress risk. Despite a bullish analyst recommendation and strong recent price performance (+50.3% 1Y), the company faces declining earnings (YoY EPS -33%), poor profit margins (0.95%), and negative insider sentiment. Valuation metrics are mixed, with a high trailing P/E of 67.20 but a low forward P/E of 9.28, suggesting expectations of recovery. However, deteriorating earnings trends, weak dividend strength, and significant insider selling undermine the bullish case.

DDS exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a very low Debt/Equity ratio of 0.31. However, the stock is significantly overvalued, trading at $595.20—nearly double its Graham Number ($305.57) and Intrinsic Value ($255.01). While profitability remains high with an ROE of 31.90%, the company is facing a growth stagnation with negative YoY revenue and earnings growth. The disconnect between strong fundamental health and poor valuation/growth metrics suggests a limited upside from current levels.